TY - JOUR
T1 - Effect of interferon-γ on allergic airway responses in interferon-γ-deficient mice
AU - Yoshida, Makoto
AU - Leigh, Richard
AU - Matsumoto, Koichiro
AU - Wattie, Jennifer
AU - Ellis, Russ
AU - O'Byrne, Paul M.
AU - Inman, Mark D.
PY - 2002/8/15
Y1 - 2002/8/15
N2 - Interferon (IFN)-γ reduces airway responses after allergen challenge in mice. The mechanisms of this effect are not clear. These studies investigate whether IFN-γ can reverse prolonged airway responses after allergen challenge in IFN-γ-deficient (IFN-γKO) mice. Sensitized mice (IFN-γKO and wild-type [WT]) were challenged with ovalbumin. Airway responsiveness, eosinophils in bronchoalveolar lavage fluid, and lung lymphocyte subsets (CD4+ and CD8+) were measured 24 hours and 8 weeks after challenge. In further experiments, we treated IFN-γKO mice with recombinant IFN-γ starting 4 weeks after the challenge for 1 week or 4 weeks. Airway responsiveness, bronchoalveolar lavage eosinophils, and lung CD4+ cells were increased 8 weeks after challenge in IFN-γKO but not WT mice. IFN-γ treatment returned lung CD4+ cell numbers to values obtained in unchallenged mice. One week of IFN-γ treatment also returned airway responsiveness to baseline levels; however, 4-week treatment with IFN-γ failed to decrease airway responsiveness below levels observed in untreated animals. This suggests that IFN-γ plays an essential role in reversing allergen-induced airway inflammation and hyperresponsiveness and that it may have dual actions on the latter. Observations that IFN-γ reverses airway responses, even when administered after challenge, suggests that IFN-γ treatment could control allergic disease, including asthma.
AB - Interferon (IFN)-γ reduces airway responses after allergen challenge in mice. The mechanisms of this effect are not clear. These studies investigate whether IFN-γ can reverse prolonged airway responses after allergen challenge in IFN-γ-deficient (IFN-γKO) mice. Sensitized mice (IFN-γKO and wild-type [WT]) were challenged with ovalbumin. Airway responsiveness, eosinophils in bronchoalveolar lavage fluid, and lung lymphocyte subsets (CD4+ and CD8+) were measured 24 hours and 8 weeks after challenge. In further experiments, we treated IFN-γKO mice with recombinant IFN-γ starting 4 weeks after the challenge for 1 week or 4 weeks. Airway responsiveness, bronchoalveolar lavage eosinophils, and lung CD4+ cells were increased 8 weeks after challenge in IFN-γKO but not WT mice. IFN-γ treatment returned lung CD4+ cell numbers to values obtained in unchallenged mice. One week of IFN-γ treatment also returned airway responsiveness to baseline levels; however, 4-week treatment with IFN-γ failed to decrease airway responsiveness below levels observed in untreated animals. This suggests that IFN-γ plays an essential role in reversing allergen-induced airway inflammation and hyperresponsiveness and that it may have dual actions on the latter. Observations that IFN-γ reverses airway responses, even when administered after challenge, suggests that IFN-γ treatment could control allergic disease, including asthma.
UR - http://www.scopus.com/inward/record.url?scp=0037102302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037102302&partnerID=8YFLogxK
U2 - 10.1164/rccm.200202-095OC
DO - 10.1164/rccm.200202-095OC
M3 - Article
C2 - 12186819
AN - SCOPUS:0037102302
SN - 1073-449X
VL - 166
SP - 451
EP - 456
JO - American Journal of Respiratory and Critical Care Medicine
JF - American Journal of Respiratory and Critical Care Medicine
IS - 4
ER -